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ABSTRACT 
Patients with pancreatic cancer have a short life expectancy, and only 20% of the patients 
diagnosed with pancreatic cancer can undergo surgery. Chemotherapy does not work well: 
Gemcitabine is the standard regimen with a 5-year survival rate of 1%–4% and a median 
survival time of 4-6 months; FOLFIRINOX chemotherapy regimen using four drugs was found 
to be more effective (median survival 11 months), but with substantial side effects. In this 
thesis, we aim to find new ways to treat pancreatic cancer by immunotherapy.  
In Paper I, we established a new protocol to expand tumor-infiltrating lymphocytes (TIL) from 
pancreatic cancer tumor tissues. Those T cells were able to recognize and kill autologous tumor 
cells, and produced Th1 signature cytokines, particularly IFN-. 
In Paper II, we identified the individual mutations in pancreatic cancers by whole-genome 
sequencing. We found that T cells from the tumor or peripheral blood could recognize the 
mutations, such as mutated K-ras. One CD4
+
 TIL clone recognized a novel (neo) epitope 
(GLLRYWRTERLF) derived from an aquaporin 1-like molecule (K7N7A8 protein product). 
Those T cells could be a source for T cell receptor (TCR) transfer to treat patients.  
In Paper III, we established tumor-infiltrating B lymphocyte (TIB) cell lines from patients with 
pancreatic cancer and patients with glioblastoma. We found that TIB produced antibodies that 
could recognize EBV and/or CMV peptides. Those peptides were also recognized by TILs. One 
CMV peptide (CEDVPSGKLFMH) showed to be recognized by TIB, TILs, peripheral T cells 
and serum antibodies from one same patient, PanTT32. Antigen-specific B cell receptors (BCR) 
from TIBs could be a source for the construction of chimeric antigen receptor (CAR) T cells. 
In Paper IV, we cultured peripheral blood cells from patients with pancreatic cancer with 
mesothelin peptides. A survival benefit was linked to IFN-γ production to peptides 
corresponding to the mature mesothelin and to targeted recognition of the mesothelin601-615 
epitope (MQEALSGTPCLLGPG; p=0.006) in the presence of IL-21. The peptide 
mesothelin601-615 could therefore be a candidate for pancreatic cancer vaccines. 
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LIST OF ABBREVIATIONS 
ADCC Antibody-dependent cell-mediated cytotoxicity 
APC Antigen-presenting cell 
AQP Aquaporin 
BCR B-cell receptor 
CAR Chimeric antigen receptor 
CD Cluster of differentiation 
CMV Cytomegalovirus 
CTL Cytotoxic T lymphocytes 
CTLA-4      Cytotoxic T-lymphocyte-associated protein- 4 
DC Dendritic cell 
DTH Delayed-type hypersensitivity 
EBNA1 Epstein–Barr virus nuclear antigen 1 
EBNA3 Epstein–Barr virus nuclear antigen 3 
EBV Epstein-Barr virus 
ELISA Enzyme-linked immunosorbent assay 
GM-CSF     Granulocyte-macrophage colony-stimulating factor 
GVHD Graft-versus-host disease 
HLA Human leukocyte antigen 
hMSCs Human bone marrow-derived mesenchymal stem cells 
HSCT Hematopoietic stem cell transplantation 
ICS Intracellular Cytokine Staining 
IDO Indoleamine-pyrrole 2,3-dioxygenase 
IgG Immunoglobulin gamma 
IFN-α            Interferon-alpha 
IFN-γ Interferon-gamma 
IL-2 Interleukin-2 
IL-15 Interleukin-15 
IL-21 Interleukin-21 
LAG-3          Lymphocyte-activation gene 3 
LMP2 Epstein–Barr virus (EBV) latent membrane protein 2 
MPF Megakaryocyte-potentiating factor 
MSCs Mesenchymal Stem Cells 
NPC Nasopharyngeal carcinoma 
PBMC Peripheral blood mononuclear cell 
PD-1             Programmed cell death protein -1 
PDAC Pancreatic ductal adenocarcinoma 
TAA Tumor-associated antigens 
TCR T-cell receptor 
TGF-β         Transforming growth factor-beta 
TIB   Tumor-infiltrating B lymphocytes 
TIL Tumor-infiltrating lymphocytes 
TIM-3       T cell immunoglobulin-and mucin-domain-containing molecule-3 
TNF-α       Tumor necrosis factor-alpha 
Tregs Regulatory T cells 
WBA Whole blood assay 
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1   INTRODUCTION 
Pancreatic ductal adenocarcinoma, also known as pancreatic adenocarcinoma, is the most 
frequent form of pancreatic cancer. With a five year survival rate of 5%, it becomes one of 
the leading causes of cancer-related death 
[1-3]
. Due to its aggressive progression, late 
clinical diagnosis and intense resistance to conventional chemotherapy and radiotherapy, 
improved and more innovative treatment modalities are urgently needed presently for 
patients with pancreatic cancer. Cancer immunotherapy (e.g. adoptive cellular 
immunotherapy) is a potential and promising strategy for cancer treatment that is expanding 
gradually into a broad and important subject in recent oncology 
[4, 5]
.   
        This thesis will focus on tumor-infiltrating lymphocytes (TILs) (including specific T 
cells and B cells) expanded from the tumor tissue of patients with pancreatic cancer and 
identification of their targets which could be used for cellular immunotherapy, and thus 
benefit the development of more effective and innovative treatment options for patients 
with pancreatic cancer. 
 
1.1  PANCREATIC CANCER BIOLOGY  
 
Pancreatic cancer is subdivided into a number of different subtypes.  Approximately 85% 
of the cases are classified as pancreatic ductal adenocarcinomas (or pancreatic 
adenocarcinomas) 
[3]
. Generally, pancreatic cancers arise from pancreatic ductal cells, of 
which almost 99% derive from the exocrine component, while around 1% comes from 
neuroendocrine cells within the pancreas 
[3]
.  
        Pancreatic cancer is associated with advancing age. More than 50% of patients are 
over the age of 70, while it rarely occurs before the age of 40 
[3, 6]
.  Besides age, other 
predisposing factors such as cigarette smoking, excessive alcohol consumption, specific 
types of food (e.g. processed or red meat) and some medical factors (e.g. chronic 
pancreatitis, diabetes and obesity) are also involved 
[3, 6, 7]
.   
        Mutations in specific genes as K-ras, CDKN2A, TP53 and SMAD4 are associated 
with the tissue evolution of pancreatic adenocarcinoma. K-ras, the most common genetic 
alteration, is located in chromosome 12p, and is present in almost 95% of pancreatic 
adenocarcinomas. It encodes a member of RAS family that affects many cellular effects 
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including proliferation, survival and differentiation 
[8-10]
. CDKN2A, the cyclin-dependent 
kinase inhibitor 2A, is a tumor-suppressor gene regulating the cell cycle, and resides on 
chromosome 9. Its mutations occur in 95% of pancreatic adenocarcinomas and are also 
linked to the familial atypical mole-malignant melanoma syndrome. Inherited CDKN2A 
mutation increases the risk of pancreatic cancer by 13 folds 
[11, 12]
. In up to 85% of 
pancreatic cancers, there is a mutation in gene TP53, which resides on chromosome 17 and 
plays an important role in cell cycle, DNA repair and apoptosis; as many as 50% of all 
TP53 mutations could lead to loss of protein expression and null alleles 
[8]
. SMAD4, 
located on chromosome 18, also called Mothers Against Decapentaplegic homolog 4 or 
Deleted in Pancreatic Cancer-4 (DPC4), is one of the Smad family proteins acting as signal 
transducers responding to TGF-β, regulating cell proliferation and apoptosis [13]. It is 
inactivated in 50% of advanced pancreatic cancers 
[14]
. 
        In the United States, pancreatic cancer is the fourth most frequent cause of human 
death 
[1, 2, 15]
. And in 2015, 411,600 deaths globally were reported to be due to pancreatic 
cancer 
[16]
. This is due to very poor prognosis. About 25% of the patients with pancreatic 
adenocarcinoma survive one year, whereas only 5% live at 5 years after diagnosis 
[3]
.  
        Currently, the treatment for pancreas adenocarcinoma includes surgery, chemotherapy, 
radiotherapy, palliative care or combinations thereof which partly depends on the cancer 
stage. Surgery is the only potentially curative option for those patients, however, no more 
than 20% are actually suitable for surgery 
[7]
. Chemotherapy such as FOLFIRINOX or 
gemcitabine can be offered to patients with good performance status after surgery, and may 
also be given to patients that are not suitable for surgery to extend or improve their lives 
[17]
. 
Gemcitabine was the first chemotherapy drug approved by FDA in 1997 for pancreatic 
cancer because of its improvements in life quality and a 5-weeks improved median survival 
duration 
[18]
. More effective than the standard gemcitabine treatment, the FOLFIRINOX 
regimen (a combination of 4 chemicals including leucovorin, fluorouracil [5-FU], 
irinotecan and oxaliplatin) was found to induce the longest improvement in survival time 
with 11.1 months (approximately 4 months longer), but had serious side effects due to its 
high toxicity 
[19]
. Thus, the FOLFIRINOX regimen is only a treatment option for those 
patients with good performance status who can tolerate the side effects 
[18]
.  
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1.2  IMMUNOTHERAPY FOR PANCREATIC CANCER 
1.2.1  T CELL IMMUNOTHERAPY  
Cellular immunotherapy with tumor specific T cells is a highly promising platform for 
treating various solid tumors, with much success observed among melanoma patients over the 
last 30 years 
[5, 20-22]
. Current efforts to develop T-cell therapies for cancer focus on 3 major 
strategies: (i) isolation and expansion of TILs; (ii) T cells transduced with transgenic T cell 
receptors (TCR) specific for tumor epitopes, or T cells heterologously expressing chimeric 
antigen receptors (CAR) which recognize tumor cell-associated surface molecules; (iii) 
enrichment and expansion of tumor antigen-reactive T cells isolated from peripheral blood 
followed by cell selection and/or TCR cloning (Figure 1).  
 
 
Figure 1. Adoptive cell therapy. Source: Cassian Yee, Adoptive T-Cell Therapy for Cancer: 
Boutique Therapy or Treatment Modality? Clin Cancer Res, 2013.  
 
        TILs are generally equipped with strong and specific anti-tumor effector functions. It is 
however a challenging task to generate TILs in the clinical setting since T-cell isolation and 
expansion from tumor tissue is not always feasible due to inter-patient variabilities. Tumor-
 4 
reactive T cells from the peripheral blood of patients with melanoma have been shown to 
contain neoantigen-specific T cells and express the programmed cell death 1 (PD-1) on 
surface 
[23]
. The chimeric antigen receptor (CAR) technology is being actively pursued by 
biopharmaceutical companies for cancer immunotherapy due to its potential for extended use. 
Briefly, a CAR molecule comprises a single-chain variable fragment (scFv) of a monoclonal 
antibody directed against a particular molecule (i.e. CD19) fused to a cytoplasmic region of a 
T cell activation molecules i.e. CD28, 4-1BB via a linker, and the CD3 zeta chain. Gene 
segments encoding these components are cloned into a lentiviral or retroviral vector for T cell 
transduction. CAR T cells recognizing human CD19 expressed on B cells are currently 
undergoing clinical testing in patients with lymphoma and B-cell leukemia. Although initial 
results are very encouraging, the lack of specific surface molecules exclusively expressed on 
cancer cells is a current limitation for an extended use. Retroviral or lentiviral vectors are also 
able to be applied to transfer TCRs with high affinity and avidity for tumor epitopes into 
autologous peripheral blood-derived T cells. The first successful clinical trial using 
genetically engineered autologous lymphocytes to induce tumor regression in metastatic 
melanoma patients was reported by Rosenberg and colleagues in 2006 
[24]
. TCRs specific for 
epitopes derived from NY-ESO-1, a cancer testis antigen, have also been utilized for patients 
with synovial cell carcinoma or melanoma 
[25]
. 
        Tumor-infiltrating lymphocytes (TILs) are a source for cancer immunotherapy. In 2016, 
we first reported the phenotype and function of expanded TILs from pancreatic cancer tumor 
tissue, and found that the TILs recognized and killed autologous tumor cells from pancreas 
(also shown in detail in paper I) 
[26]
. Later in the same year, two other research groups also 
showed in their publications that TILs could be obtained from patients with pancreatic cancer 
[27, 28]
. Compared to them, we got more CD8
+
T cells by using IL-2, IL-15 and IL-21 cytokines 
in our method.  
 
1.2.2  Regulatory T cells  
Regulatory T cells (Tregs) are immunosuppressive, and can efficiently suppress or down-
regulate induction and proliferation of effector T cells. Thus, Tregs exist to help regulate the 
strength of an inflammatory immune response and maintain tolerance to self-antigens. This, 
in turn establishes an equilibrium in cell-mediated immunity, and reduces the risk of 
developing autoimmune diseases 
[29]
. Tregs are categorized as CD4 T cells which show high 
expression of surface CD25, along with no CD127 expression and they are positive for the 
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transcription factor fork head box P3 (FoxP3), also known as scurfin, and require TGF-β 
signal for differentiation from naïve CD4+ cells as well as cellular homeostasis 
[30]
. It is 
noteworthy that surface expression of CD103 is a hallmark of tumor-infiltrating Tregs in vitro 
and in vivo 
[31]
. Ademmer and colleagues have previously reported that among TILs isolated 
from pancreatic cancer tissue, approximately 8% of CD4
+
 T cells and 20% of CD8
+
 T cells 
are CD103
+
 
[32]
. Furthermore, there was a large variation (from 9% to 32%) observed for the 
distribution of CD103 expression in CD8
+
 lymphocytes, and this T cell subset was found 
interestingly restricted only to the fibrous interstitial tissue without periductally or 
intraepithelially, indicating of their roles in disease progression of pancreatic cancer 
[32]
.  
 
1.2.3  Immune checkpoint inhibitors  
Tumor-specific T cells express four main immune checkpoint molecules on their surface 
which abrogate effective anti-tumor responses within the tumor microenvironment: PD-1, 
CTLA-4 (cytotoxic T-lymphocyte associated protein 4), LAG-3 (lymphocyte-activation gene 
3) and TIM-3 (T-cell immunoglobulin and mucin-domain containing 3). Therapeutic 
targeting of PD-1 and CTLA-4 in melanoma using monoclonal antibodies has been highly 
successful, with one anti-CTLA-4 reagent and at least two clinically approved anti-PD-1 
reagents in market. Further clinical studies with newer candidates are in progress, such as 
anti-TIM-3 and anti-LAG-3 monoclonal antibodies. As previously mentioned, PD-1 
expression on CD8
+
 T cell isolated from tumor tissues as well as peripheral blood of patients 
with metastatic melanoma are now known to recognize neoantigens, and can respond to them 
in vitro with IFN-γ and TNF-α production; potent cytotoxic killing of autologous tumor cells 
by PD-1
+
 CD8
+
 TILs has also been observed 
[33]
. Blockade of PD-1 in patients with 
metastatic melanoma has been shown to unleash the anti-tumor activity of CD8
+
 TILs which 
are specific for neoantigens, leading to durable clinical responses 
[34]
. Check point inhibitors 
such as anti-CTLA-4 and anti-PD1 antibody, improved the survival time for melanoma and 
lung cancer patients 
[35, 36]
. However, in a phase II trial, ipilimumab (fully humanized anti-
CTLA4 antibody) was ineffective and did not prolong survival for 27 patients with locally or 
advanced metastatic pancreatic cancer 
[37]
.    
        It is now well known that tumor cells express surface molecules that inhibit the anti-
tumor activity of T cells. The upregulation of surface programmed cell death 1 ligand 1 (PD-
L1, also known as B7-H1) – which interacts with PD-1 on the surface of T cells to diminish 
their anti-tumor potential – is a major setback to activate an efficacious immune responses to 
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kill tumor cells 
[38]
. Anti-PD-L1 monoclonal antibodies are also employed in clinical trials for 
various cancers. Pre-screening patients for PD-L1 expression on the tumor cells prior to 
initiating therapy may provide an early indication for the chances of treatment success. 
        PDL1 and indoleamine-pyrrole 2, 3-dioxygenase (IDO) are expressed by tumor and 
infiltrating immune cells and could be upregulated by IFN-γ. This forms a feedback loop 
inducing a PD-1 signal that holds immunosuppression dominantly. The immunosuppressive 
tumor microenvironment is the principle reason why many immunotherapies aiming to 
directly trigger the antitumor immune response failed 
[39] 
.  
1.2.4  B cells  
B cells function as antigen-presenting cells (APCs), which are well-known for production of 
antibodies against broad antigens and can also produce cytokines (Table 1) 
[40]
. We found that 
EBV-B cells also could produce IL-21 which is important for memory T cells (unpublished 
data). A Japan research group in 2015 found that the tumor infiltrating B lymphocytes (TIB) 
represent a good positive prognostic factor for pancreatic cancer. TIBs were antigen-
experienced and secreted antibodies which can bind to allogeneic tumor cell lines 
[41]
. These 
antibodies may also have reactivity to neoantigens and could potentially be developed further 
to therapeutic agents. Identification of the tumor specific antibodies from TIBs to be used to 
engineer CAR T cells could be a novel way to treat cancer.  
Table 1.  Cytokine production from B lymphocytes and EBV transformed B cells 
Cytokines* Fresh B cells LCLs* 
IL-1, 2, 3, 4, 6, 10, 13 + + 
INF-γ + + 
IL-7 _ + 
LT-β + _ 
GM-CSF + _ 
G-CSF, M-CSF + + 
* LCL, lymphoblastoid cell line; IL, interleukin; IFN, interferon; LT, lymphotoxin; GM-CSF, 
granulocyte-macrophage colony-stimulating factor; G-CSF, granulocyte colony-stimulating factor; M-
CSF, macrophage colony-stimulating factor. 
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        By immunostaining, we found that there were both TILs and TIBs in pancreatic cancer 
tumor tissue (Figure 2). I have established the TIB cell lines from tissues of both pancreatic 
cancer and brain tumors. They produced high levels of IgG and or IgA antibodies 
(Unpublished data). In 1996, Williams S. found that the TIB from lung cancer could produce 
tumor-specific IgG detected by Western Blotting 
[42]
. Staoru Imahayashi showed similar 
results in the year of 2000 
[43]
. B cells may also express Fas ligand with the potential to kill 
autologous tumor cells 
[44]
.  
 
 
Figure 2. Microphoto of pancreas cancer tumor tissue with immunostaining CD3 (brown) & CD20 
(Red); taken by Carlos Fernández Moro & Qingda Meng 
    
        Recent studies have shown that certain B cells especially B1 B cells, which produce high 
levels of IgM, can promote the growth of pancreatic cancer or metastasis 
[45-47]
. TIB not only 
can be a source for B cell receptor (BCR) to get individual CAR T cells, but also a target for 
pancreatic cancer therapy. 
 
1.2.5  Dendritic cells (DCs) and vaccine 
Dendritic cells form an essential connection between the innate and adaptive immune 
responses. It has been previously reported that DCs requires the type I interferon for tumor 
rejection 
[48, 49]
. DC-based cancer vaccines represent a promising area of investigation for 
cancer immunotherapy. 
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        MUC1 is overexpressed in pancreatic cancer and it can be recognized by cytotoxic T 
lymphocytes and antibodies 
[50]
. MUC1 is used for DC-based cancer vaccine against 
pancreatic cancer 
[51]
. A phase I/II trial of a DC vaccine loaded with MUC1 peptide for 
patients with pancreatic and biliary cancer, showed that four of the twelve patients are alive at 
four years after vaccination without recurrence  
[52]
.  
        In an additional report, three of 14 patients were observed to have a  more than 25 
months of disease-free survival time in a trial for a GM-CSF-secreting pancreatic tumor 
vaccine and this vaccine could induce delayed-type hypersensitivity (DTH) responses against 
the autologous tumor 
[53]
. Subsequent studies by the same group showed that the mesothelin 
specific CD8
+
 T cells were induced by this vaccine for those three patients 
[54]
. In a phase I/II 
trial for a K-ras vaccine with 48 patients with pancreatic cancer enrolled, one individual 
single mutant K-ras peptide has been reported to be derived from the patient tumor mutations 
or a mixed mutant K-ras  including G12D, G12C, G12V and G12R combined with GM-CSF; 
this K-ras peptide vaccine could significantly increase the responder survival time (148 days) 
as compared to non-responders (61 days) 
[55]
. 
        In this thesis, we found that there were a quite high percentage of mesothelin specific 
CD8
+
 T cells among TILs. We identified one mesothelin peptide, mesothelin601-615 
(MQEALSGTPCLLGPG) to be dominant in this response. The immune response (IFN-γ 
production) for this particular peptide was linked to a survival benefit. Our data suggested 
that mesothelin601-615 could be a new peptide epitope to be used for a pancreatic cancer 
vaccine.  We have established various TIL cell lines from patients with pancreatic cancer. 
Among them, a TIL cell line and tumor cell line were from patient Panc17, and the TILs 
showed a very high IFN- response (453 pg/mL) to mutated K-ras, after three times 
stimulation with the autologous tumor cell line. 
 
1.2.6  Cytokine immunotherapy  
IFN-α is the first cytokine shown to provide anti-tumor effects for patients with progressive 
melanoma. In phase I/II trials of IFNα, almost 20% of patients with metastatic disease were 
observed to get objective tumor regression 
[56, 57]
. Early in the year of 1995, recombinant IFN-
α-2b was approved by FDA in the US as the first adjuvant immunotherapy to treat patients 
with stage IIB/III melanoma. 
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        Interleukin (IL)-2 plays an essential role in regulating the immune system and T cell 
proliferation.  It was shown in clinical trials that recombinant IL-2 had significant anti-tumor 
activity for patients with progressive metastatic melanoma 
[58-61]
. 
        IL-15, as a T-cell growth factor, is secreted by phagocytes such as dendritic cells and 
macrophages, having effects on both T cells and natural killer cells. IL-15b can inhibit the 
antigen-induced cell death (AICD) of T cells, reverse T cell anergy and active natural killer 
cells 
[62-64]
.  
        IL-21, which is mainly produced by activated CD4
+
 memory T cells, is a member of the 
-chain family of cytokines [65, 66]. When acting with IL-7 or 15 together, it is able to stimulate 
naïve and memory CD8
+
 T cell to expand, and raise the affinity to tumor-reactive antigen-
specific CTL clones 
[65, 67]
. IL-21 also inhibits the CD80 and CD86 expression on immature 
DCs, and suppresses DC activation and cytokine production 
[68, 69]
. It has been demonstrated 
that IL-21 could promote tumor rejection and immune memory, and avoid metastases 
[68, 69]
. 
IL-21 can be critical when in vitro generating and expanding tumor antigen-specific CTL 
lines/clones from PBMCs or TILs used for adoptive immunotherapy. 
 
1.2.7  Mesenchymal Stem Cells (MSCs) engineered for Cancer Therapy 
Mesenchymal Stem Cells (MSCs) are able to be recruited into solid organs when reacting to 
tissue stress. Because of its tropism for brain tumors, human bone marrow-derived 
mesenchymal stem cells (hMSCs) can possibly be applied as potent delivery vehicles to treat 
gliomas. It was reported in 2005 that after isolating and fluorescently labelling hMSCs, Akira 
and coworkers injected the cells to mice bearing human glioma xenografts and observed that 
these cells were only restricted in the brain tumors, whereas widespread distribution of 
delivered cells was induced by fibroblasts or U87 glioma cells without tumor specificity 
[70]
.  
        HMSC-IFN-β is MSCs that has been engineered to releasse IFN-β, which was reported 
to be able to treat human glioma xenografts in vivo and notably prolong the survival of 
animals as compared to control group 
[70]
. Similar to HMSC-IFN-β, transplanted MSCs that 
produce IL-18 was related to improved T cell infiltration and prolonged anti-tumor effects in 
mice with gliomas 
[71]
. Oncolytic adenoviruses loaded MSC was found capable of 
suppressing the growth of glioma and markedly improving animal survival to eliminate 
tumors when compared with the control group 
[72]
. MSC can also delivery other cytokines 
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including IL-2, 12 and IFN-, as well as drugs. Figure 3 is the summary of the use of MSC 
therapy in cancer. 
 
 
Figure 3.  Transgene strategies potentiating MSC for tumor. Source: Khalid Shah, Adv Drug Deliv 
Rev, 2012. 
 
        MSCs have advantages of easy availability and handling in vitro, non-immunogenic 
nature,  and an ability of preferentially migrating towards local inflamed tissue, which make 
them very promising candidates for cell based treatment options 
[73]
.  
        I hypothesize that MSCs after engineered with IL-2/15/21 may deliver these cytokines to 
the tumor tissue. Thus, transfer of MSCs together with tumor specific TILs to patients could 
be a more powerful therapy for cancer. 
 
1.2.8  Natural killer (NK) cell therapy 
In contrast to cytotoxic T lymphocytes (CTLs), the anti-tumor effects of NK cells are antigen-
independent. Especially, it is possible to use both autologous NK cells and allogeneic ones. 
IgG Fc receptors (FcγRIII, CD16) are highly expressed on the CD56dim NK cell subset, which 
can regulate ADCC, the antibody-dependent cellular cytotoxicity 
[74]
. NK cell activity is 
dependent of NKG2D and NCRs (natural cytotoxicity receptors)  for receptor activations, and 
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relies on inhibitory receptors such as KIRs (killer immunoglobulin-like receptors) for 
receptor suppression. KIRs interact with human leukocyte antigen (HLA) class I molecules. 
Besides, inhibitory receptor NKG2A is also able to bind to non-classical HLA class I, HLA-E 
[75]
.  
        In 2005, Miller and coworkers first established and published the safety and efficacy 
report about adoptive transfer of haploidentical NK cells, whereas nineteen patients with 
acute myeloid leukemia (AML) received the cell infusions and IL-2, and complete remission 
was observed in all of the five patients 
[76]
. NK cells are appealing to CAR expression 
because of its cytotoxic function and not causing graft-versus-host disease (GVHD) that is 
different from T cells 
[77]
. However, in pancreatic cancer, there are very few NK cells 
detected to infiltrate into the tumor tissue 
[32]
.  
 
1.2.9  Hematopoietic Stem Cell Transplantation (HSCT) 
Allogeneic HSCT is primarily used for patients with hematologic malignancies 
[78]
. Studies 
showed that HSCT had also effects for solid tumors, e.g. renal cell carcinoma 
[79-81]
, 
colorectal cancer 
[82, 83]
 and ovarian cancer 
[84]
.  
        In 2009, Yasunobu Abe reported a study using HSCT for five patients with pancreatic 
cancer, and found that 2 patients showed tumor reduction (one with tumor disappearance, 
whereas the other approximately 20% reduction) 
[85]
. Additionally in 2016, Brigitta Omazic 
and Olle Ringdén from our division (Therapeutic Immunology, Karolinska Institutet), 
reported in a long-term follow-up study of HSCT for solid cancer (pancreatic cancer 
included) that three patients with pancreatic cancer were treated with HSCT, 2 of which were 
alive and cancer-free 8 years after HSCT 
[86]
. A subsequent study in the year of 2017 showed 
that two patients developed immune responses against INO80E and UCLH3, two tumor-
associated antigens after HSCT 
[87]
. 
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2   AIMS 
The general aims of this thesis were: 
1) To expand tumor specific T cells from pancreatic cancer tumor tissue, characterize their 
phenotype, function and specificity, and also identify their targets, which could potentially be 
used for cellular immunotherapy. 
2) To identify targets of tumor-infiltrating B lymphocytes (TIBs), as BCR from the TIBs 
could then be used for CAR T cells, and identified epitope could be used as a tumor vaccine. 
3) To understand the relation between the peripheral blood immune reactions against 
mesothelin and overall survival, and to identify if the mesothelin epitopes were associated 
with overall survival of the patients.   
  
Specific aims: 
 To expand tumor specific T cells from pancreatic cancer tumor tissue with IL-2, IL-
15 and IL-21, and test the T cell phenotype, function, specificity and clonality (Paper 
I). 
 To identify mutations in tumors by whole-genome sequencing, using this informatin 
to synthesize neoepitopes, and to identify T cell targets by culturing TILs with 
neoepitope peptides (Paper II). 
 To identify EBV and CMV epitopes recognized by tumor-infiltrating B lymphocytes 
and/or tumor-infiltrating T lymphocytes. Map the response to these epitopes among 
peripheral T cells and serum antibodies from patients with pancreatic cancer or 
glioma (Paper III). 
 To explore the relationship between immune reactions against a tumor associated 
antigen (mesothelin) and patients overall survival, and to identify specific mesothelin 
epitopes (Paper IV). 
 
  
  13 
3   MATERIALS AND METHODS  
3.1  PERIPHERAL BLOOD AND TUMOR TISSUE 
Peripheral blood and tumor tissue samples from patients with pancreatic cancer or brain 
tumors were obtained from Karolinska hospital, Sweden after informed consent. The study 
was approved by the regional ethical review board at Karolinska Institutet, Stockholm, 
Sweden (Dnr: 2013/977-31/1, Dnr: 2013/1332-31/3 and Dnr: 2013/576-31).  
 
3.2  CELL LINE ESTABLISHMENT  
In these studies, we have established tumor-infiltrating T lymphocytes cell lines, tumor-
infiltrating B lymphocytes cell lines and pancreatic cancer tumor cell lines. Tumor tissues 
from clinical biopsies or surgery were cut with surgical scissors and a scalpel. Individual 
single tumor fragments (1–2 mm3) were placed in each well of a 24-well tissue culture plate.   
        Tumor-infiltrating T lymphocytes were cultured with Cellgro GMP Serum-free medium 
(Cell-Genix, Freiburg, Germany) with 10% human AB serum (Innovative Research, MI) 
supplemented with IL-2 (1000 IU/mL), IL-15 (10 ng/mL) and IL-21 (10 ng/mL). (Paper I, II 
and III) 
        Tumor-infiltrating B lymphocytes were cultured with 70% Cellgro GMP-grade serum-
free medium (CellGenix, Freiburg, Germany), 20% B95-8 supernatant containing EBV virus, 
10% FBS (Life Technologies). (Paper III) 
        Pancreatic cancer cell lines were cultured with RPMI 1640 with 10% FBS (Life 
Technologies), epidermal growth factor (EGF, 20 ng/mL; ImmunoTools, Friesoythe, 
Germany). When tumor cell lines were established, the cells were cultured and passaged 
without EGF. (Paper I and II) 
 
3.3  WHOLE-BLOOD ASSAY (WBA) 
Peripheral blood was diluted 5x with RPMI 1640 (1 blood: 4 RPMI 1640), with or without 
recombinant human IL-21 (10 ng/ml; Prospec, Rehovot, Israel) in 96-well plates (200l 
diluted blood/well). The diluted blood was stimulated with different antigens. Anti-human 
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CD3 antibody (OKT3) was used as positive control and cells without stimulation (medium 
only) as negative control. Supernatants were harvested after 7 days incubation at 37
o
C with 
5% CO2. 
        The supernatants were used for IFN-γ ELISA test. (Paper IV) 
 
3.4  ELISA  
IFN-γ was detected by sandwich ELISA (Mabtech, Stockholm, Sweden) after T cells or 
diluted peripheral blood cells were co-cultured with peptides, OKT3 or tumor cells. (Paper I, 
II, III and IV) 
 
3.5  FLOW CYTOMETRY  
We used a 12 color flow cytometer (FACS Aria) to measure the TIL phenotypes, exhaustion 
level and TCR Vβ repertoire, as well as for testing T cell function by CD107a assay and 
intracellular cytokine staining (ICS). (Paper I and II) 
        In paper I, antibodies for phenotype characterization: CD3, CD4, CD8, CD45RA, 
CCR7, CD107a, C-kit and CD127; Antibodies for activation/exhaustion: CD3, CD4, CD8, 
CD45RA, CCR7, 4-1BB, CD127, LAG-3, CD25, TIM3, PD-1 and CTLA-4; Antibodies used 
for ICS panel were: CD3, CD4, CD8, IL-2, IL-17, IFN-γ and TNF-α; Antibodies used for 
TCR Vβ panel were: CD3, CD4, CD8 and TCR Vβ Repertoire Kit (Beckman Coulter) which 
measures 24 TCR Vβ with antibodies in 8 tubes. 
        In paper II, antibodies for phenotyping: CD3, CD4, CD8 and CXCR3; Antibodies for 
CD107a assay: CD3, CD4, CD8 and CD107a. 
 
3.6  CR51 RELEASE ASSAY 
Chromium 51 (Cr
51
) release assay was performed in paper I to detect cytotoxic T-cell 
responses. 
        The tumor target cells were labeled with Na2CrO4 at 37
o
C for 1 hour. After washing 
with PBS, the Cr
51
 labeled tumor cells were co-cultured with TILs in a 96-well plate at 
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10,000 cells/well for 4 hours at 37
 o
C, 5% CO2. After 4 hours of incubation, the Cr
51
 
radioactivity from each well was measured with 1450 MicroBeta Trilux scintillation counter. 
The percentage of specific lysis was calculated with the negative control and positive control. 
 
3.7  PEPTIDE MICROARRAY  
In Paper III, peptide microarray chips embedded with 12-mer peptides were used from CMV 
and EBV proteins: CMVpp65, EBNA1, EBNA3, LMP2 and BMLF1. The 12-mer peptides 
with a 11-amino acid overlap were selected to cover the five protein sequences entirely. 
These five proteins were spanned by a total number of 3067 peptides, with seven technical 
replicates for each peptide on the chip. Goat Anti-Human IgG, Fcγ Fragment Specific was 
used as detection antibodies. After incubation, the microarrays were scanned with a 
NimbleGen MS200 scanner and the signal was extracted with internal Roche software called 
SlideViewer.  
 
3.8  WHOLE-GENOME SEQUENCING  
Genomic DNA from patient samples (tumor tissues and TILs) was fragmented to construct an 
Illumina DNA library. DNA exons were captured and analyzed. Tumor mutations were 
determined by comparing to both the reference human genome sequence and non-malignant 
cell sequence from the same patient.   
 
3.9  IMMUNOSTAINING  
In Paper II, pancreatic cancer tumor tissues were performed with immunohistochemistry and 
stained with CD3-CD20 or CD4-CD8 antibodies. CD3 and CD4 antibodies were labeled with 
3, 3'-diaminobenzidine (DAB) (brown), while CD20 and CD8 with alkaline phosphatase 
(AP) (red). The tissues for staining were selected by Dr. Carlos Fernández Moro, a specialist 
pancreatic pathologist.  
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3.10  STATISTICS  
In Paper IV, survival probability was evaluated using Kaplan-Meier survival analysis and 
log-rank test. The cut-off median values of antigen-specific IFN-γ production were 
determined based on the intensity of the response to each antigenic stimulus tested.  
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4   RESULTS AND DISCUSSION 
 
4.1  PAPER I 
 
“Expansion of Tumor-reactive T Cells from Patients with Pancreatic Cancer” 
In PAPER I, we generated TILs from surgical or biopsy specimens from 17/17 patients 
with pancreas cancer using the IL-2/IL-15/IL-21 cytokine cocktail. Our data showed that 
the combination of IL-2, IL-15 along with IL-21 is capable of expanding TILs with a 
preference for central (CD45RA
-
CCR7
+
) and effector (CD45RA
-
CCR7
-
) memory subsets 
(Figure 4). It has been reported that central-memory T cells exhibit stronger proliferative 
potential and are perhaps the best candidates to provide long-term antitumor reactivity 
[88, 
89]
.  
 
 
Figure 4.  TIL Immunophenotype 
 
        TILs were observed to have a low expression of exhaustion marks such as CTLA-4 
and TIM3. However, the PD-1 expression was high in CD8
+
 T cells (median 36%). LAG-3
+
 
cells were frequent in CD8
+
 T cells with 96% as compared to almost 2% in CD4
+
 T cells 
(median). 
       By analyzing the TCR Vβ families in TILs with flow cytometry, we found that twelve 
of 17 TILs expressed preferential expansion of certain TCR Vβ families (e.g. 99.2% 
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Vβ13.2 in CD8+ T cell from Panc9 and 77% Vβ1 in CD8+ T cell from Panc1).  
        Mesothelin, survivin and NY-ESO-1, the commonly shared tumor-associated antigens 
(TAAs), were also found to be recognized by TILs (Figure 5). NY-ESO-1 acts as one of the 
cancer-testis antigens 
[90]
, and could induce specific HLA class I- and class II-restricted T 
cell responses 
[91, 92]
. We observed strong IFN-γ and TNF-α induction of TILs upon NY-
ESO-1 exposure, e.g. up to 8.2% and 12.0% in CD8
+
 TILs from patient Panc6 (Figure 5).  
 
 
 
Figure 5.  Frequency of TAA-reactive T cells defined by IFN-γ and TNF-α intracellular cytokine 
staining in TILs from patients with pancreatic cancer. Right panel: ICS analysis of IFN-γ and TNF-
α production after NY-ESO-1 stimulation in CD8+ and T cells from Panc 6 TILs. 
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        TILs could recognize and kill autologous tumor cells. The Panc9 TILs (a Vβ13.2 
CD8
+ 
T cell line) prompted IFN-γ production against autologous tumor cells (Figure 6A), 
which were able to be blocked by anti-MHC-I antibody, whereas not by MHC-II. Panc17 
TILs were found to be able to kill autologous tumor cell line through a standard chromium 
51 release assay (Figure 6B).  
    
 
Figure 6.  (A) IFN- production in TILs after co-culture with autologous tumor cells (Panc 9); (B) 
Recognition of autologous tumor cell line in Panc17 (PanTT26) TILs by a chromium 51 release assay. 
 
        Taken together, our results presented in PAPER I show that: Pancreatic cancer TILs 
with a Th1 profile can be reliably expanded; Individual TIL cell lines can recognize 
commonly shared TAAs and response to autologous tumor cells; Preferential expansion of 
TCR Vβ families in TILs has been associated with antigen-driven expansion [93]. Taken 
together this all suggests that IL-2/IL-15/IL-21-driven expansion of pancreatic cancer TILs 
indicates a feasible source for cells to be used for cancer immunotherapy.  
 20 
4.2  PAPER II 
 
“Neoepitopes as targets for Tumor-infiltrating Lymphocytes from Patients with 
Pancreatic Cancer” 
Neoantigens are host proteins harboring point mutations that are disease-associated i.e. 
cancer, from which peptide sequences containing specific mutated amino acids, namely 
neoepitopes can be derived. These structures reflect ‘private mutations’ that are unique 
from patient to patient, thus representing an individually tailored and highly specific 
antigen signature 
[94]
. As such, neoantigen/neoepitope-directed approaches are clinically 
relevant for refining T cell immunotherapies and cancer vaccines. Studies have previously 
shown that extraordinary clinical responses were induced by specialized T cell-based 
therapies selecting private mutations of patients with metastatic cancers as targets 
[95-97]
. 
The identification of neoepitopes described in our studies employed a highly sophisticated 
method, which involves whole exome sequencing using genomic DNA from patients’ 
tumor material, followed by in silico processing of data and application of bioinformatic 
prediction algorithms. In PAPER I, we successfully isolated and expanded TILs from 
human pancreatic cancer tumor with a cocktail of the gamma chain cytokines IL-2, IL-15 
and IL-21. In addition, we demonstrated that these TILs could recognize and kill 
autologous pancreatic cancer tumor cells. Thus, analysis of the immune response of TILs to 
patient-specific neoepitopes potentially expressed by autologous tumor cells – based on 
cytokine (IFN-γ and/or TNF-α) response and/or cytotoxic activity (CD107a induction) – 
would enable a thorough screening platform to identify legitimate immunogenic targets in 
human pancreatic cancer, an idea which led to the studies reported in PAPER II.  
        We have established TILs and tumor cell lines from patient Panc17. Since IFN-γ 
production by TILs was negatively reversed by adding the W6/32 (anti-HLA class I) 
antibody to the TIL:tumor cell co-culture, the anti-tumor effect of Panc17 TILs thus 
reflected a dominant HLA class I-restricted, CD8+ T cell-mediated activity. Accordingly, 
we observed that the composition of TILs was approximately 59% of the CD8
+
 T cells and 
22% CD4
+
 T cells – the number of CD8+ T cells almost 3 times that of the CD4+ T cells. 
We also observed that stimulating the TILs with the autologous tumor cells enriched for 
CD8
+
 T cells (almost 100%), which displayed strong immune responses (IFN-γ production) 
directed against mutated host peptides, including one neoepitope derived from the K-RAS 
protein (KLVVVGAVGVGKSAL). Thus, we concluded that it is highly likely that TILs 
from patient Panc17 contained several neoepitope-specific T cells that can be expanded and 
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activated with the IL-2, -15 and -21 cytokine cocktail as well as autologous tumor cells. 
        From patient Panc39, we were able to isolate a CD4+ TIL clone recognizing a 
neoepitope (GLLRYWRTERLF) derived from an aquaporin (AQP)-like molecule 
(K7N7A8 protein product). In fact, the AQP2 gene mutations, which result in aberrantly 
expressed protein products, have been related to the onset of autosomal nephrogenic 
diabetes insipidus 
[98]
. Even though weak binding of potentially pathogenic IgG molecules 
(pertinent to the neurodegenerative disease neuromyelitis optica) has been demonstrated to 
be induced by site-specific AQP4 mutations 
[99]
, there is still no report about clinically 
relevant immune responses to mutant AQP proteins. As far as we know, the study presented 
in PAPER II is the first to describe the productive anti-tumor responses directed against a 
mutant epitope derived from an AQP-like molecule, and furthermore mediated by CD4
+
 
TILs. Importantly, we also noticed that the CD4
+
 TIL clone reactivity to the 
GLLRYWRTERLF neoepitope was dose-dependent, and was amenable to blockade by the 
L243 antibody (anti-HLA-DR), but not by the W6/32 antibody (anti-HLA-A/B/C), further 
affirming that GLLRYWRTERLF involved a nominal HLA class II neoepitope.  
        TILs and PBMCs derived from patient Panc77 were compared for T-cell recognition 
pattern of mutant targets, defined by IFN-γ production. Six mutant epitopes recognized by 
TILs and PBMCs, while other neoepitopes showed exclusive recognition by either TILs 
(nine mutated peptides) or PBMCs (five mutated peptides). An interesting TIL-specific 
neoepitope target was derived from PPP1R15B (Protein Phosphatase 1 Regulatory Submit 
15B), as part of an enzyme that dephosphorylates the eukaryotic translation initiation factor 
2A when cells are under stress and has been reported to exhibit pro-oncogenic 
characteristics in breast cancer 
[100]
. 
        Identifying and characterizing neoepitope-specific cellular immune responses presents 
a revolutionary therapy platform for treating patients with advanced cancers. Our aim 
therefore is to make the findings presented in this thesis (thus, scientific articles) a clinical 
reality – developing the next generation T-cell based immunotherapies for patients with 
pancreatic cancer, even including individuals ineligible for surgery.  
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4.3  PAPER III 
 
“Peptide microarray identifies novel CMV and EBV targets recognized by tumor-
infiltrating T lymphocytes and antibodies in pancreatic cancer and glioma” 
As previously mentioned, TILs perform a key role in regulating immune responses in the 
tumor microenvironment, conversely influencing the clinical outcome in patients with solid 
cancers e.g. melanoma, pancreatic cancer and glioma 
[101-105]
. Even though T cells are the 
major component of TILs, a substantial and noteworthy proportion of these cells also 
comprise tumor-infiltrating B cells (TIB). In essence, TIBs, together with their T-cell 
counterparts, actively shape and participate in mediating intratumoral immune responses 
[41, 
106]
. Besides of processing and presenting antigens to organize local cellular immune 
response, TIBs are capable of producing effector cytokines such as IFN-γ, TNF-α and IL-
10 
[41]
. It is also important that TIBs – which are differentiated into plasma cells – secrete 
antibodies against TAAs or persistent viral antigens e.g. those derived from 
cytomegalovirus (CMV) and Epstein-Barr virus (EBV).  
        Intact immune responses against CMV and EBV, and the ability to effectively contain 
infection without causing disease manifestation serve as a crucial indication of the immuno-
physiological fitness of an individual 
[107-109]
. Targeted immune responses to these 
pathogens seem to link with positive clinical outcomes in patients with cancer. Even there 
already have large details about human T-cell reactivity to CMV and EBV proteins, the IgG 
responses therein still have not been thoroughly investigated for solid cancers, thus as the 
background for the study presented in PAPER III.   
        In this paper, we showed for the first time that anti-CMV and anti-EBV humoral 
immune responses exist in the tumor microenvironment, defined by TIB-derived IgG 
reactivity to viral epitopes in vitro. This was performed on a high content peptide 
microarray chip embedded 12-mer peptides with 11-mer overlapping sequences spanning 
entire proteins from CMV (pp65) and EBV (EBNA-1a, EBNA-3, BMLF1, LMP2) – which 
are major antigens from these pathogens. We also confirmed that TIB-IgG responses were 
more diverse than serum IgG response, whereas serum IgG response was usually more 
restricted hence focused. TIB-derived IgG molecules can broadly recognize viral targets, 
which may therefore represent a unique imprint of humoral immune responses in the tumor 
microenvironment.  
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        There might also be a role for virus (CMV/EBV)-specific T cells in human cancer. A 
report earlier this year showed in mouse model of melanoma that CMV-specific T cells had 
capacity of infiltrating tumor lesions without loss of functionality, in spite of PD-1 
expression 
[110]
. T-cell epitopes are possibly recognized also by antibodies and provide a 
valuable platform for diagnosis, e.g. formerly demonstrated in the context of NY-ESO-1-
mediated immune responses in patients with cancer 
[90, 111, 112]
. In line with this, we also 
found that the TILs from the same patients showed reactivity (IFN-γ production) to CMV 
and EBV peptides that were at first recognized by the TIB-derived IgG. Interestingly, one 
particular CMV peptide (CEDVPSGKLFMH) was recognized by TIB-IgG, TIL, PBMCs 
and serum-IgG from a patient with pancreatic cancer (PanTT32). 
        Antigen-specific T-cell responses and therapy thereof can induce tumor regression and 
may improve the survival of patients with advanced cancer 
[23, 33, 113]
. In accord, it is highly 
plausible that virus-specific adaptive immune cells presenting in cancer lesions i.e. TIL and 
TIB play a biologically relevant role in mediating anti-tumor responses. Our data showed 
that the immune responses directed against CMV and EBV antigens in cancer are 
heterogeneous, because of their both patient- and disease-specific. This antiviral immune 
response could potentially be exploited as yet another novel immunotherapeutic strategy to 
treat advanced cancers. Indeed, administration of a CMV pp65-based cellular vaccine to 
patients with glioblastoma was recently shown to contribute to increased survival 
[114]
. 
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4.4  PAPER IV 
 
“Prediction of improved survival in patients with pancreatic cancer via IL-21 
enhanced detection of mesothelin epitope-reactive T-cell responses” 
Novel immunogenic targets as well as biomarkers which can regulate biologically and 
clinically relevant immune responses in while enabling better diagnosis of cancer are now 
urgently needed. Mesothelin is a cell surface-bound TAA and expressed by mesothelial 
cells lining various internal organs, such as the pericardium, peritoneum, pancreas, and 
pleura 
[115]
. Mesothelin has been identified to be overexpressed in a number of cancers 
including mesothelioma, ovarian cancer, colorectal cancer, lung cancer and pancreatic 
cancer, and usually in its native form 
[115-119]
. Furthermore, the expression of mesothelin has 
been reported in almost all pancreatic ductal adenocarcinomas 
[120-122]
. Structurally, 
mesothelin consists of: i) the megakaryocyte-potentiating factor (MPF), which is cleaved 
by furin after being translocated to the cell surface and shed into systemic circulation, and ii) 
the cell surface-bound GPI-anchored mature mesothelin component with overexpression in 
tumor tissues 
[115]
. We therefore asked the question whether mature mesothelin possess a 
prognostic role and how this might be related to immune responses and survival in 
pancreatic cancer.  
        PAPER IV is the first report to show that IL-21 conditioning promotes mesothelin-
specific T cell responses, based on IFN-γ production in PBMCs. Furthermore, this 
enhanced cellular immune response correlates with the increased survival of patients with 
pancreatic cancer who were also surgically treated. A crucial point presented in this study is 
that only the mature mesothelin component but not the shed MPF component of full-length 
mesothelin is associated with survival of the patients with pancreatic cancer. In particular, 
immune responses to the immunodominant MQEALSGTPCLLGPG peptide (mature 
mesothelin, aa 601-615) is a single target that is independently linked to better patient 
survival profile. We therefore concluded that mesothelin-directed IFN-γ responses provide 
a clinically relevant immunological readout associated with improved clinical outcome in 
patients with pancreatic cancer. 
        IL-21, which belongs to the family of gamma chain cytokines, can maintain the 
function and survival of memory CD8+ T cells, as well as aiding their proliferation in vitro 
after isolation from clinical samples sourced by patients with melanoma or pancreatic 
cancer 
[123]
. The IL-21/IL-21 receptor pathway in T cells also facilitates better 
immunological control of viral and bacterial infection 
[124]
. It was shown that IL-21 
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inhibited the expression of forkhead box P3 (FoxP3), the cardinal transcription factor linked 
with Tregs in conjunction after encountering cancer cells – just like TGF-β blockade [125]. 
Our previous report demanstrated that the combination of IL-2, IL-15 and IL-21 increases 
the population of central memory TILs from pancreatic cancer and glioma, following ex 
vivo expansion 
[26]
 
[125]
. 
        Mesothelin epitopes have been previously described to be recognized by CD8+ T cells 
[54, 126, 127]
. In PAPER IV, we established a previously unknown link between the 
mesothelin601-615 epitope (MQEALSGTPCLLGPG) and improved survival of patients with 
pancreatic cancer but in the presence of IL-21 conditioning. This peptide may therefore 
have implications for rational vaccine design, T-cell expansions as well as a novel cancer 
biomarker.  
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5   CONCLUSION AND FUTURE POSSIBILITIES 
The work of this thesis showed a new protocol to culture tumor-infiltrating lymphocytes 
using IL-2, IL15 and IL-21 cytokines. Cells presented low exhaustion markers after 
expansion and could recognize and kill autologous tumor cells. We identified targets of T 
cells and TIBs. We also detected a specific immune response to a single peptide p41 
mesothelin601-615 epitope (MQEALSGTPCLLGPG), which is associated with the improved 
patient survival.  
        The future work following the study reported in Paper I and II would be to obtain the 
TCR for tumor mutation epitopes, such as the TCR for aquaporin 1-like protein (K7N7A8) in 
adoptive immunotherapy. We found that Vβ2 and Vβ9 in PanTT39 could recognize 
autologous tumor cells; therefore, the next step would be to identify the location of antigen-
specific T cells in the tissue by TCR Vβ immunostaining.  
        In paper III, we found that TIB and TIL recognize certain EBV and CMV peptides, 
which are different from the peptides recognized by serum antibodies. In the future, we may 
choose to sequence BCR from the TIB and TCR from the TIL as well to identify EBV and 
CMV specific BCR/TCR for engineering EBV and/or CMV specific CAR T cells for cancer 
therapy. The identified peptides that TIBs and TILs recognize can be used as candidates for 
anti-cancer vaccines. 
        In Paper IV, we identified the peptide 41 (P41), mesothelin601-615 epitope 
(MQEALSGTPCLLGPG), which is associated with improved patient survival. We therefore 
would like to measure the serum antibody against the peptide and analyze the relationship 
between antibody levels and patient survival, and use this peptide for pancreatic cancer 
vaccine. By culturing PBMCs with p41, we could obtain specific T cells for p41, selecting 
those T cells by flow cytometry, and sequence the TCR in order to engineer p41 specific T 
cells which could be used  for targeting mesothelin-positive cancers. 
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